PepGen Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • PepGen's estimated annual revenue is currently $16.9M per year.(i)
  • PepGen's estimated revenue per employee is $155,000

Employee Data

  • PepGen has 109 Employees.(i)
  • PepGen grew their employee count by 22% last year.

PepGen's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
VP, Bioanalytical, Biomarkers and DMPKReveal Email/Phone
5
Head Corporate Strategy and Business Development Reveal Email/Phone
6
VP, Global Regulatory AffairsReveal Email/Phone
7
VP, Quality AssuranceReveal Email/Phone
8
VP, Finance & ControllerReveal Email/Phone
9
SVP Chemistry & ManufacturingReveal Email/Phone
10
VP, ToxicologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is PepGen?

keywords:N/A

N/A

Total Funding

109

Number of Employees

$16.9M

Revenue (est)

22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

PepGen News

2022-04-17 - PepGen Targets IPO For Duchenne Muscular Dystrophy Treatments

PepGen has filed to raise funding via a U.S. IPO. The firm is developing treatment candidates for Duchenne Muscular Dystrophy and related...

2022-03-30 - PepGen Announces First Participant Dosed in a Phase 1 ...

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy.

2022-03-22 - PepGen Continues to Build Leadership Team with Additions ...

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M10931%N/A
#2
$27.6M10912%N/A
#3
$19.6M1096%N/A
#4
$29.4M1099%N/A
#5
$16.4M1092%N/A